Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Exact Sciences Corporation (EXAS)

64.66   -0.75 (-1.15%) 03-24 12:21
Open: 64.55 Pre. Close: 65.41
High: 65.38 Low: 63.86
Volume: 376,981 Market Cap: 11,589(M)

Technical analysis

as of: 2023-03-24 12:00:48 PM
Stoxline posted a SELL today, downgraded from higher rating. Downward movement to be expected.
Target: Six months: 81.12     One year: 94.75
Support: Support1: 63.29    Support2: 59.47
Resistance: Resistance1: 69.45    Resistance2: 81.12
Pivot: 64.73
Moving Average: MA(5): 64.83     MA(20): 64.31
MA(100): 55.55     MA(250): 49.53
MACD: MACD(12,26): 0.3     Signal(9): 0.3
Stochastic oscillator: %K(14,3): 44.3     %D(3): 47.3
RSI: RSI(14): 51.1
52-week: High: 76.94  Low: 29.27
Average Vol(K): 3-Month: 2,496 (K)  10-Days: 1,762 (K)

Price, moving averages and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.
[ EXAS ] has closed above bottom band by 49.6%. Bollinger Bands are 56% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 4 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 68.03 - 68.36 68.36 - 68.66
Low: 63.84 - 64.21 64.21 - 64.55
Close: 64.82 - 65.38 65.38 - 65.92

Company Description

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for breast, prostate, and colon cancers; Oncotype Test, a tissue test delivering tumor profiling to aid therapy selection for patients with advanced, metastatic, refractory, or recurrent cancer; Oncotype DX AR-V7 Nucleus Detect Test, a liquid-based test for advanced stage prostate cancer; Oncomap ExTra, that provides a complete biological picture of certain refractory, rare, or aggressive cancers; and Covid-19 testing services. The company's pipeline products focus on enhancing the Cologuard test's performance characteristics and developing blood and other fluid-based tests. It has license agreements with MAYO Foundation for Medical Education and Research; and Hologic, Inc. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.

Headline News

Thu, 23 Mar 2023
Exact Sciences (EXAS) Outpaces Stock Market Gains: What You Should Know - Zacks Investment Research

Thu, 23 Mar 2023
Beech Hill Advisors Inc. Sells 15935 Shares of Exact Sciences Co ... - MarketBeat

Sat, 18 Mar 2023
Peregrine Capital Management LLC Grows Holdings in Exact ... - MarketBeat

Thu, 16 Mar 2023
Exact Sciences Corp (EXAS) is higher by 1.62% in a Week, Should You Accumulate? - InvestorsObserver

Tue, 14 Mar 2023
Exact Sciences (EXAS) Gains But Lags Market: What You Should ... - Nasdaq

Thu, 09 Mar 2023
Exact Sciences Corp (EXAS) is higher by 2.48% Thursday In Premarket Trading - InvestorsObserver

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Neutral
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Neutral
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Outperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Diagnostics & Research
Shares Out. 178 (M)
Shares Float 176 (M)
% Held by Insiders 0.9 (%)
% Held by Institutions 90.4 (%)
Shares Short 13,070 (K)
Shares Short P.Month 11,890 (K)

Stock Financials

EPS -3.49
EPS Est Next Qtl -0.29
EPS Est This Year -1.17
EPS Est Next Year -0.71
Book Value (p.s.) 17.1
Profit Margin (%) -30
Operating Margin (%) -29.8
Return on Assets (ttm) -6.1
Return on Equity (ttm) -19.4
Qtrly Rev. Growth 16.7
Gross Profit (p.s.) 8.47
Sales Per Share 11.67
EBITDA (p.s.) -2.38
Qtrly Earnings Growth 0
Operating Cash Flow -224 (M)
Levered Free Cash Flow -268 (M)

Stock Valuations

PE Ratio -18.6
PEG Ratio -0.3
Price to Book value 3.78
Price to Sales 5.54
Price to Cash Flow -51.59

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.